Title: SUCCESSFUL THERAPY WITH TENOFOVIR DISOPROXIL FUMARATE (TDF)
IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) DOES NOT GUARANTEE
AMELIORATION OF LIVER DAMAGE ASSESSING BY TRANSIENT ELASTOGRAPHY.
A RETROSPECTIVE - PROSPECTIVE MULTICENTER STUDY
Version: 1 Date: 20 Dec 2023
Reviewer's report:
Entecavir, Tenofovir dispoproxil fumarate, and Tenofovir alafenamide are the third generation
nucleos(t)ide analogs recommended as first-line monotherapy by all international guidelines
for treating of chronic hepatitis B (CHB).  These drugs achieve sustained on-treatment viral
suppression in more than 95% of patients, resulting in several clinical benefits such as prevention
of cirrhosis and liver decompensation, improvement of liver histology, and often reversion of
histologic cirrhosis. However, HCC can still develop and it is currently the major complication
in the long-term management of CHB patients. In this Paper, the Authors aimed to address the
changes in liver stiffness assessed by transient elastography in CHB patients receiving long-term
TDF in a real-world setting and to investigate non-virological parameters that are associated with
fibrosis regression or progression. Their results confirmed that successful long term TDF therapy
had a beneficial effect in liver fibrosis, specially in patients with advanced fibrosis or cirrhosis.
Interestingly in this study, despite sustained virological response, ¼ of patients had progressive
liver disease due to non-virologic factors implicated in liver damage such as metabolic factors.
The Paper is very well written and the results are very interesting. I feel that it can be considered
for publication.
Title: SUCCESSFUL THERAPY WITH TENOFOVIR DISOPROXIL FUMARATE (TDF)
IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) DOES NOT GUARANTEE
AMELIORATION OF LIVER DAMAGE ASSESSING BY TRANSIENT ELASTOGRAPHY.
A RETROSPECTIVE - PROSPECTIVE MULTICENTER STUDY
Version: 1 Date: 20 Dec 2023
Reviewer's report:
Entecavir, Tenofovir dispoproxil fumarate, and Tenofovir alafenamide are the third generation
nucleos(t)ide analogs recommended as first-line monotherapy by all international guidelines
for treating of chronic hepatitis B (CHB).  These drugs achieve sustained on-treatment viral
suppression in more than 95% of patients, resulting in several clinical benefits such as prevention
of cirrhosis and liver decompensation, improvement of liver histology, and often reversion of
histologic cirrhosis. However, HCC can still develop and it is currently the major complication
in the long-term management of CHB patients. In this Paper, the Authors aimed to address the
changes in liver stiffness assessed by transient elastography in CHB patients receiving long-term
TDF in a real-world setting and to investigate non-virological parameters that are associated with
fibrosis regression or progression. Their results confirmed that successful long term TDF therapy
had a beneficial effect in liver fibrosis, specially in patients with advanced fibrosis or cirrhosis.
Interestingly in this study, despite sustained virological response, ¼ of patients had progressive
liver disease due to non-virologic factors implicated in liver damage such as metabolic factors.
The Paper is very well written and the results are very interesting. I feel that it can be considered
for publication.
Please review this paper.
user
Title: SUCCESSFUL THERAPY WITH TENOFOVIR DISOPROXIL FUMARATE (TDF)
IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) DOES NOT GUARANTEE
AMELIORATION OF LIVER DAMAGE ASSESSING BY TRANSIENT ELASTOGRAPHY.
A RETROSPECTIVE - PROSPECTIVE MULTICENTER STUDY
Version: 1 Date: 20 Dec 2023
Reviewer's report:
Entecavir, Tenofovir dispoproxil fumarate, and Tenofovir alafenamide are the third generation
nucleos(t)ide analogs recommended as first-line monotherapy by all international guidelines
for treating of chronic hepatitis B (CHB).  These drugs achieve sustained on-treatment viral
suppression in more than 95% of patients, resulting in several clinical benefits such as prevention
of cirrhosis and liver decompensation, improvement of liver histology, and often reversion of
histologic cirrhosis. However, HCC can still develop and it is currently the major complication
in the long-term management of CHB patients. In this Paper, the Authors aimed to address the
changes in liver stiffness assessed by transient elastography in CHB patients receiving long-term
TDF in a real-world setting and to investigate non-virological parameters that are associated with
fibrosis regression or progression. Their results confirmed that successful long term TDF therapy
had a beneficial effect in liver fibrosis, specially in patients with advanced fibrosis or cirrhosis.
Interestingly in this study, despite sustained virological response, ¼ of patients had progressive
liver disease due to non-virologic factors implicated in liver damage such as metabolic factors.
The Paper is very well written and the results are very interesting. I feel that it can be considered
for publication.
assistant